Karim Bitar (February 11, 1965 – October 26, 2025) was an American businessman. He was the chief executive officer of Convatec from 2019 to 2025.[1]
Born in New York City to middle eastern parents, he graduated from the University of Wisconsin and earned an MBA at the University of Michigan's Ross School of Business in 1992.[2] He began his career as a McKinsey & Company consultant and later worked for Eli Lilly, before becoming the CEO of Genus plc, a company which specialized in animal genetics. He was a non-executive director of Spectris from 2017 to 2022. Bitar died from pancreatic cancer on October 26, 2025, at the age of 60.[3]
References
- ^ John, Jamie (November 27, 2025). "Convatec revives itself after post-private equity slump". Financial Times. Retrieved November 29, 2025.
- ^ "Karim Bitar". Michigan Ross. Retrieved November 29, 2025.
- ^ "Karim Bitar obituary: healthcare chief executive". The Times. Retrieved November 29, 2025.
 | This United States biographical article is a stub. You can help Wikipedia by adding missing information. |
